Novartis Institutes for BioMedical Research Inc. 13D and 13G filings for Ayala Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-10-31 4:00 pm Unchanged | 2022-10-19 | 13G | Ayala Pharmaceuticals, Inc. AYLA | Novartis Institutes for BioMedical Research Inc. | 698,777 4.700% | 0 (Unchanged) | Filing |
| 2021-02-05 5:17 pm Purchase | 2020-12-31 | 13G | Ayala Pharmaceuticals, Inc. AYLA | Novartis Institutes for BioMedical Research Inc. | 698,777 5.500% | 698,777 (New Position) | Filing |